INCY vs. HOLX

Last updated Jun 3, 2026

INCY (Incyte Corporation) and HOLX (Hologic, Inc.) are both stocks. Both are in the Healthcare sector — INCY in Biotechnology, HOLX in Medical Instruments & Supplies. At a 0.27 correlation, their price movements are largely independent.

Performance

INCY vs. HOLX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Incyte Corporation (INCY) and Hologic, Inc. (HOLX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

INCY

• 1D: -3.50%
• 1M: -4.82%
• YTD: -6.61%
• 6M: -9.07%
• 1Y: 41.23%
• 3Y*: 13.83%
• 5Y*: 2.16%
• 10Y*: 0.83%

HOLX

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

INCY vs. HOLX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
INCY Incyte Corporation	-6.61%	43.00%	10.00%	-21.83%	9.43%	-15.61%	-0.39%	37.32%	-32.86%	-5.55%
HOLX Hologic, Inc.	2.04%	3.33%	0.90%	-4.49%	-2.29%	5.12%	39.49%	27.03%	-3.86%	6.56%

Correlation

The correlation between INCY and HOLX is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.27
Correlation (3Y) Calculated over the trailing 3-year period	0.26
Correlation (5Y) Calculated over the trailing 5-year period	0.29
Correlation (10Y) Calculated over the trailing 10-year period	0.34
Correlation (All Time) Calculated using the full available price history since Nov 5, 1993	0.27

Fundamentals

Market Cap INCY : $19.08B HOLX : $17.17B
EPS INCY : $7.06 HOLX : $2.41
PE Ratio INCY : 13.07 HOLX : 31.54
PS Ratio INCY : 3.49 HOLX : 4.16
PB Ratio INCY : 3.39 HOLX : 3.27
Total Revenue (TTM) INCY : $5.36B HOLX : $4.13B
Gross Profit (TTM) INCY : $3.76B HOLX : $2.18B
EBITDA (TTM) INCY : $1.80B HOLX : $1.01B

Return for Risk

INCY vs. HOLX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

INCY

INCY Risk / Return Rank: 75
INCY Sharpe Ratio Rank: 77
INCY Sortino Ratio Rank: 74
INCY Omega Ratio Rank: 71
INCY Calmar Ratio Rank: 76
INCY Martin Ratio Rank: 75

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

INCY vs. HOLX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Incyte Corporation (INCY) and Hologic, Inc. (HOLX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	INCY	HOLX	Difference
Sharpe ratio Return per unit of total volatility	1.28	—	—
Sortino ratio Return per unit of downside risk	1.97	—	—
Omega ratio Gain probability vs. loss probability	1.24	—	—
Calmar ratio Return relative to maximum drawdown	2.28	—	—
Martin ratio Return relative to average drawdown	5.15	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	INCY	HOLX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.28	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.07	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.02	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.20	—	—

Drawdowns

Drawdown Indicators

	INCY	HOLX	Difference
Max Drawdown Largest peak-to-trough decline	-98.54%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-18.33%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-33.83%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-41.53%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-66.47%	—	—
Current Drawdown Current decline from peak	-39.58%	—	—
Average Drawdown Average peak-to-trough decline	-59.92%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	8.11%	—	—

Volatility

Volatility by Period

	INCY	HOLX	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.43%	—	—
Volatility (6M) Calculated over the trailing 6-month period	22.29%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	32.37%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	29.24%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	34.23%	—	—

Dividends

INCY vs. HOLX - Dividend Comparison

Neither INCY nor HOLX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

INCY vs. HOLX - Profitability Comparison

The chart below illustrates the profitability comparison between Incyte Corporation and Hologic, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

INCY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Incyte Corporation reported a gross profit of 0.00 and revenue of 1.27B. Therefore, the gross margin over that period was 0.0%.

HOLX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Hologic, Inc. reported a gross profit of 586.40M and revenue of 1.05B. Therefore, the gross margin over that period was 56.0%.

INCY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Incyte Corporation reported an operating income of 301.12M and revenue of 1.27B, resulting in an operating margin of 23.7%.

HOLX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Hologic, Inc. reported an operating income of 237.00M and revenue of 1.05B, resulting in an operating margin of 22.6%.

INCY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Incyte Corporation reported a net income of 303.33M and revenue of 1.27B, resulting in a net margin of 23.8%.

HOLX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Hologic, Inc. reported a net income of 179.10M and revenue of 1.05B, resulting in a net margin of 17.1%.

Frequently Asked Questions

Can I hold both INCY and HOLX in my portfolio?

INCY and HOLX have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.